WT warrants -another peice of brilliant work by stagezero. Stage did a short extension of warrants so shareholders could buy, however there was a catch (James and Rebecca thought it was a good deal).
The highest price of the warrants was $0.12, 8 warrants were required to purchase (because of the earlier reverse split). So at 8X 0.12 = $0.96 plus the exercise price of $0.72 for a grand total of $1.68. Let us say you had bought the warrants for $0.02 each, so 8x.02 =$0.16 plus $0.72 = $0.88.
Who in their right mind would purchase a stock using those warrants when the stock price at the time was in the 21-23 cent range. Sheer madness.
The holders of those warrants were hosed. They looked like a good deal at the time of issue, the expiry date was three years out and that stage would increase its' stock price and hold it, but no the Care Oncology acquistion killed it and the stock plummeted.
Brilliant work Stagezero. Because the warrants expired valueless Stagezero never received a thin dime for people exercising the warrants, for example 720,606 warrants @ 0.72 = $520,276, half a million dollars and Stage blew it, no wonder we are in the mess we are in now.
StageZero Life Sciences, Ltd. announces that it has applied to the Toronto Stock Exchange to extend the expiry date of 5,702,314.00 outstanding common share purchase warrants (the “Warrants”) to January 31, 2023.
TORONTO, ON / ACCESSWIRE / February 4, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) (“StageZero” or the “Company”), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that it has applied to the Toronto Stock Exchange (the “Exchange”) to extend the expiry date of 5,702,314.00 outstanding common share purchase warrants (the “Warrants”) to January 31, 2023. The Warrants consist of certain of the Company’s Warrants that are currently due to expire in 2022.
The Warrants were originally issued pursuant to non-brokered private placements and debenture conversions. None of the Warrants to be extended are held, directly or indirectly, by any insiders of the Company.
The following table identifies the Warrants and their exercise price.
| Issue Date | Exercise Price | Current Expiry Date | Number of Warrants |
| 25-Mar-2019 | 0.72 | 25-Mar-2022 | 722,606.00 |
| 23-Apr-2019 | 0.8 | 23-Apr-2022 | 390,626.00 |
| 23-Apr-2019 | 0.96 | 23-Apr-2022 | 220,797.00 |
| 23-Apr-2019 | 1.528 | 22-Apr-2022 | 319,095.00 |
| 10-Jul-2019 | 1.48 | 10-Jul-2022 | 1,448,597.00 |
| 24-Jul-2019 | 1.48 | 24-Jul-2022 | 566,875.00 |
| 19-Feb-2020 | 0.56 | 19-Feb-2022 | 202,344.00 |
| 08-Jul-2020 | 0.56 | 18-Feb-2022 | 31,250.00 |
| 09-Jul-2020 | 0.56 | 18-Feb-2022 | 78,125.00 |
| 28-Sep-2020 | 0.56 | 18-Feb-2022 | 50,782.00 |
| 29-Sep-2020 | 0.56 | 18-Feb-2022 | 54,688.00 |
| 27-Oct-2020 | 0.56 | 18-Feb-2022 | 15,625.00 |
| 25-Jan-2021 | 0.56 | 18-Feb-2022 | 62,500.00 |
| 28-Jan-2021 | 0.56 | 18-Feb-2022 | 273,438.00 |
| 29-Jan-2021 | 0.56 | 18-Feb-2022 | 490,625.00 |
| 29-Jan-2021 | 0.56 | 18-Feb-2022 | 343,750.00 |
| 25-Feb-2021 | 0.56 | 18-Feb-2022 | 23,438.00 |
| 01-Mar-2021 | 0.56 | 18-Feb-2022 | 9,375.00 |
| 09-Mar-2021 | 0.56 | 18-Feb-2022 | 234,375.00 |
| 25-Mar-2021 | 0.56 | 18-Feb-2022 | 31,250.00 |
| 18-Aug-2021 | 0.56 | 18-Feb-2022 | 62,500.00 |
| 19-Aug-2021 | 0.56 | 18-Feb-2022 | 69,653.00 |
The effective date for amendments to the Warrants will be February 18, 2022, subject to the requisite approval of the Exchange.
“Responding to requests from the shareholders who have participated in previous financings, we have decided to extend the term of warrants granted during these financings, to show support for those who participate, and as a possible ongoing source of capital to fund our continuing growth - up to C$5.654 million should all of the warrants be exercised - we have applied to the TSX to extend the terms of these warrants to January, 2023" said James Howard-Tripp, Chairman and CEO of StageZero. “We thank these shareholders for their continuing support”.